Breast cancer (BC) is the most common malignancy among females worldwide. Breast cancer is a highly heterogeneous malignant tumor which is constitutive of different subtypes according to the status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her-2), with diverse clinical performance, biological characteristics and prognosis. Despite early diagnosis and comprehensive treatment, especially the development of endocrine therapy, molecular targeted therapy and the emerging immunotherapies, the mortality of breast cancer has still remained relatively high. Therefore, identification of novel biomarkers for therapeutic targets and efficacy prediction of breast cancer is urgently required.
The vast majority of the human genome is made up of non-coding RNA (ncRNA), apart from about 2% protein-coding genes. ncRNAs, including circular RNA (circRNA), circular RNAs (circRNAs), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs), have been one of the hot spots in recent years. So far, a large number of ncRNAs have been recognized and found to be dysregulated in various types of cancer including breast cancer. Several ncRNAs have been reported to play critical roles in various biological processes of breast cancer, including cell proliferation, apoptosis, migration, invasion, angiogenesis, differentiation and drug resistance. Moreover, the potential of ncRNAs as diagnostic, prognostic biomarkers, and therapeutic targets has also been explored extensively in breast cancer. Accumulating studies indicating the significance of ncRNAs in the regulation of breast cancer development and drug resistance accelerated the investigation to explore the potential ncRNAs-based therapeutics in breast cancer patients. The main advantage of ncRNA based therapeutics is that it can target multiple coding or non-coding genes that regulate specific or redundant pathways involved in cancer development. However, therapeutics based on ncRNAs encounter some obstacles, such as problems associated with the delivery, potential off-target effects, and safety.
In this topic, we aim to collect original research articles, reviews, mini-reviews, commentaries and opinions focused on the recent advances of non-coding RNAs in breast cancer. Topics of interest include, but are not limited to:
1) Identification of new non-coding RNAs.
2) Non-coding RNAs as diagnosis and prognosis biomarkers of breast cancer.
3) The new mechanism of non-coding RNAs regulating the development of breast cancer.
4) Developing non-coding RNAs-based therapeutics in breast cancer.
Breast cancer (BC) is the most common malignancy among females worldwide. Breast cancer is a highly heterogeneous malignant tumor which is constitutive of different subtypes according to the status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her-2), with diverse clinical performance, biological characteristics and prognosis. Despite early diagnosis and comprehensive treatment, especially the development of endocrine therapy, molecular targeted therapy and the emerging immunotherapies, the mortality of breast cancer has still remained relatively high. Therefore, identification of novel biomarkers for therapeutic targets and efficacy prediction of breast cancer is urgently required.
The vast majority of the human genome is made up of non-coding RNA (ncRNA), apart from about 2% protein-coding genes. ncRNAs, including circular RNA (circRNA), circular RNAs (circRNAs), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs), have been one of the hot spots in recent years. So far, a large number of ncRNAs have been recognized and found to be dysregulated in various types of cancer including breast cancer. Several ncRNAs have been reported to play critical roles in various biological processes of breast cancer, including cell proliferation, apoptosis, migration, invasion, angiogenesis, differentiation and drug resistance. Moreover, the potential of ncRNAs as diagnostic, prognostic biomarkers, and therapeutic targets has also been explored extensively in breast cancer. Accumulating studies indicating the significance of ncRNAs in the regulation of breast cancer development and drug resistance accelerated the investigation to explore the potential ncRNAs-based therapeutics in breast cancer patients. The main advantage of ncRNA based therapeutics is that it can target multiple coding or non-coding genes that regulate specific or redundant pathways involved in cancer development. However, therapeutics based on ncRNAs encounter some obstacles, such as problems associated with the delivery, potential off-target effects, and safety.
In this topic, we aim to collect original research articles, reviews, mini-reviews, commentaries and opinions focused on the recent advances of non-coding RNAs in breast cancer. Topics of interest include, but are not limited to:
1) Identification of new non-coding RNAs.
2) Non-coding RNAs as diagnosis and prognosis biomarkers of breast cancer.
3) The new mechanism of non-coding RNAs regulating the development of breast cancer.
4) Developing non-coding RNAs-based therapeutics in breast cancer.